Adcentrx Therapeutics to Present First Clinical Data for ADC Candidate ADRX-0706 at 2025 ASCO Annual Meeting

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...

April 24, 2025 | Thursday | News
HUTCHMED Completes Enrollment in Phase II Registration Trial of Savolitinib for MET-Amplified Gastric Cancer

HUTCHMED (China) Limited (“HUTCHMED”)  announces that it has completed enrollment of the registration phase of its Phase II trial of savol...

April 22, 2025 | Tuesday | News
Akeso Secures NMPA Approval for Ebdarokimab to Treat Moderate-to-Severe Plaque Psoriasis in Adults

Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...

April 21, 2025 | Monday | News
Atelerix Partners with MineBio to Launch Cryo-Free Cell Preservation Technology in China

Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...

April 16, 2025 | Wednesday | News
Radiance Biopharma Doses First Patient in China in Phase 1 Trial of ROR-1 Targeting ADC RB-164™

Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...

April 16, 2025 | Wednesday | News
Kelun-Biotech’s TROP2 ADC Shows Strong Results in TNBC and NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company")  announced that results from a Phase 3 registrational clinical study evaluating...

April 14, 2025 | Monday | News
China’s Telitacicept Sets New Benchmark in gMG Treatment with Landmark Phase 3 Results

Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...

April 09, 2025 | Wednesday | News
Innocan Pharma Advances Global Patent Strategy with Divisional Application for Liposome-Based CBD Technology in China

 Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for it...

April 08, 2025 | Tuesday | News
Keymed Biosciences' IL-4Rα Antibody Stapokibart Shows Promising Results in Phase III Trial for Seasonal Allergic Rhinitis

Keymed Biosciences Inc. announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...

April 07, 2025 | Monday | News
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
Akeso Advances Global Leadership in Bispecific Antibodies with Approvals for Ivonescimab and Cadonilimab

Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...

March 31, 2025 | Monday | News
China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
Junshi Biosciences' Toripalimab (LOQTORZI®) Approved in Singapore for First-Line Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 27, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close